2022年1月19日 · SER-109 is an investigational microbiome therapeutic composed of purified Firmicutes spores for the treatment of recurrent C. difficile infection.

2023年4月27日 · Called SER-109, the pill is a cocktail of bacteria that can prevent recurring infections of C. difficile bacteria in people who have had previous episodes, and help them maintain healthy levels...

2022年1月20日 · SER-109 is an investigational microbiome therapeutic composed of purified Firmicutes spores for the treatment of recurrent C. difficile infection.

SER-109 is an investigational microbiome therapeutic composed of purified Firmicutes spores for the treatment of recurrent C. difficile infection.

“These results suggest that our investigational microbiome therapeutic, SER-109, is a potentially fast-acting intervention that can provide durable relief from recurrent C. difficile infections when administered to vulnerable patients,” said Matthew Henn, Ph.D., Chief Scientific Officer at Seres.

2023年5月10日 · The FDA has approved Seres Therapeutics and Nestlé’s SER-109, now called Vowst, for the prevention of recurrence of Clostridioides difficile infection following antibiotic treatment.

2023年4月26日 · With today's decision, SER-109 becomes the first-ever FDA-approved oral microbiome therapeutic. SER-109 was developed by the biotechnology company Seres Therapeutics, and works to restore the gut by competing metabolically with C diff and restoring colonization resistance.

SER-109 is a potential first-in-class oral investigational microbiome therapeutic comprised of purified Firmicutes spores designed to repair the disrupted microbiome after treatment with standard-of-care antibiotics.

2021年6月15日 · SER-109, an investigational microbiome drug of donor-derived, purified spores, reduced recurrence in a dose-ranging, phase (P) 1 study in subjects with multiple rCDIs. Methods: In a P2 double-blind trial, subjects with clinical resolution on standard-of-care antibiotics were stratified by age (< or ≥65 years) and randomized 2:1 to single-dose ...

SER-109 was developed to provide a scaffolding of Firmicutes bacteria that lead to an ecologic succession of compositional and functional changes in the microbiome, which reduce the risk of CDI recurrence after antibiotic-mediated disruption. The safety profile of SER-109 was similar to placebo with mainly mild or moderate AEs.